期刊文献+

中医药防治伊立替康所致迟发性腹泻研究述评 被引量:8

Review on Prevention and Treatment of Irinotecan-induced Delayed Diarrhea with TCM Treatment
在线阅读 下载PDF
导出
摘要 中医药在治疗伊立替康所致的迟发性腹泻中显现出独特的疗效。以整体观为指导,运用脏腑辨证、气血津液辨证的理论,可明显改善化疗所致肠毒性出现的腹泻、腹痛,改善患者的生存质量,但不同化疗药物致腹泻的作用机制又存在特异性和不同辨证特点,中医中药的成分及其配伍规律相对复杂,而相关的现代药理实验研究较少,仍然处在探索阶段。同时,针对不同的病因病机以及相应证候,疾病的模型只是建立于动物基础之上,对于人体复杂的证候情况不能够正确的模拟,使临床辨证施治存在较大困难。今后应致力于寻找更为准确的作用靶点,深入研究蛋白和基因表达,并明确该疾病可能影响肠道各个环节的治疗,并进一步研究非药物治疗。另外,可加强对针刺、艾灸、灌肠、耳穴贴敷、中药脐敷等治疗方法的临床研究,为治疗伊立替康所致的迟发性腹泻寻找更有效的方法。 In treatment of irinotecan-induced delayed diarrhea,TCM can achieve good clinical efficacy with the overall concept being guiding principle. By using of syndrome differentiations of Zang and Fu as well as blood and body fluids,the quality of life of patients can be significantly improved in treatment of chemotherapy-induced. However,the mechanisms of different chemotherapyinduced diarrhea are relatively complex,and the relevant researches with modern pharmacology are still at in the exploratory stage.At the same time,the animal modeling of the disease is not adequately match that with different human syndromes,so there is a big difficulty in studying the treatment according to human syndrome differentiations. Therefore,future researches should be conducted to find out more treating methods,such as the in-depth studies of proteins and gene expression and the further studies of TCM special therapies such as acupuncture,moxibustion,enema,ear sticking and medicine umbilical treatment to enhance the clinical efficacy in treatment of irinotecan-induced delayed diarrhea.
出处 《中医学报》 CAS 2016年第10期1455-1460,共6页 Acta Chinese Medicine
基金 江苏省科技厅临床医学科技专项项目(BL2014099)
关键词 迟发性腹泻 伊立替康 中医药疗法 delayed diarrhea irinotecan Chinese medicine therapy
  • 相关文献

参考文献60

  • 1李佐法.抗癌新药——伊立替康注射液[J].中国医院药学杂志,2011,31(2):140-143. 被引量:7
  • 2Fujiwara Y, Minami H. An overview of the recent progress in irinote- can harmacogenetics [J 1. Pharmacogenomics, 2010, 11 ( 3 ) : 391 -406.
  • 3Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabo- lite, SN-38:review of bioanalytical methods and recent update from clinical pharmacology Perspectives [J]. Biomed Chromatogr,2010,24 (1) :104 -123.
  • 4孙华君,王翠松.伊立替康肠毒性预防研究进展[J].世界临床药物,2005,26(5):286-291. 被引量:23
  • 5Sabharwal A, Kerr D. Chemotherapy for colorectal cancer in the meta- static and adjuvant setting: past, present and future [J]. Expert Re- view of Anticancer Therapy,2014,7 (4) :477 - 487.
  • 6Stein, Alexander, Voigt, et al. Chemotherapy-induced. diarrhea: patho- physiology, frequency and guideline-based management [J]. Thera- peutic Advances in Medical Ontology,2010,2( 1 ) :51 -63.
  • 7Sanghani SP, Quinney SK, Fredenburg TB, et al. Hydrolysis of irinote- can and its oxidative metabolites ,7-ethyl-10-[4-N-( 5-aminopentano- ic acid ) -1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4- ( I -piperidino) -I -amino] -carbonyloxycamptothecin, by human arbox- ylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3 [J]. Drug Metab Dispos ,2004,32 (5) :505 - 511.
  • 8Sai K, Salto Y, Maekawa K, et al. Additive effects of drug transporter genetic polymorphisms on iriuotecan pharmacokine-tics/pharmacody- namics in Japanese cancer patients [J]. Cancer Chemother Pharma- col,2010,66(1 ) :95 - 105.
  • 9Deeken JF, Slack R, Marshall JL. Irinotecan and uridine diphosphate glucronosy hransferase 1 A1 pharm acogeneties:to test or not to test, that is the question[J]. Cancer,2008,113(7) :1502 -1510.
  • 10Vander JM, Mathijssen RH, Creemers GJ, et al. A CYP3A4 Pheno- type-Based Dosing Algorithm for Individualized Treatment of Irinote- can[J] Clin Cancer Res,2010,16(2) :736 -742.

二级参考文献174

共引文献173

同被引文献85

引证文献8

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部